Compare Ginkgo Bioworks Holdings Inc (DNA) vs Solaredge Technologies Inc (SEDG) Price & Performance

Ginkgo Bioworks (DNA) trades at $12.84, up 11.94% in the last session. The stock shows a bullish technical signal with strong moving average support, though oscillators are neutral. Fundamentally, the company reported a net loss of $312.76 million in 2025 on $170.16 million revenue, with a negative net margin of 219.6%. Recent news includes a $17.5 million ARPA-H subcontract for RNA medicine manufacturing, highlighting strategic growth initiatives despite financial challenges.

Outlook remains speculative with high risk. The buy/hold/sell analyst split is nearly even, reflecting uncertainty. Significant cash burn and persistent losses pose substantial risks, but partnerships and government contracts offer potential catalysts. Investors should weigh the company's long-term biotechnology prospects against its current lack of profitability and negative cash flow.

SolarEdge Technologies (SEDG) trades at $33.16, down 2.59% on the day, amid a bearish technical signal and mixed earnings history. The company reported a net loss of $405.45 million in 2025, with a negative net margin of -34.24%, though revenue improved to $1.18 billion. Recent news highlights an ongoing fraud investigation by Pomerantz Law Firm and ambitious long-term revenue targets of $2.4 billion by 2029, alongside new AI data center initiatives developed with NVIDIA.

The outlook remains challenging due to persistent losses and high debt, but analyst consensus suggests modest upside with a $37.75 price target. Key risks include execution on growth targets, competitive pressures, and macroeconomic headwinds affecting solar project financing. Institutional sentiment is cautious, with 56.25% hold ratings.